Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MISTOSUS: Iscador P in Relapsed Resectable Osteosarcoma
NCT05726383Phase 2Recruiting
- Sponsor
- Hackensack Meridian Health
- Start
- May 2024
- Primary completion
- Dec 2028
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Iscador P in osteosarcoma (OS), sponsored by Hackensack Meridian Health. Primary endpoint: Event Free Survival at 12 months. Started May 2024; status: recruiting.
02
Drugs
Iscador P
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT05726383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05726383.